Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New study pursues the impact of pregnancy on drug efficacy

28.11.2002


Drs. Vadivel Ganapathy (left) and Puttur D. Prasad are part of National Institutes of Health Program Project grant looking at whether pregnant women should continue to take many common medications at the same dose as before pregnancy.


The human placenta (pictured left and schematic description on the right) ensures that baby gets proper nutrients and oxygen but it may also interfere with the blood levels of some common medications that women continue to take during pregnancy.

Click here for full size image


Whether pregnant women with conditions ranging from ulcers to AIDS should keep taking the same doses of medicine they took before pregnancy is a question Medical College of Georgia researchers want answered.

They are betting they’ll find that to maintain efficacy, pregnant women will need higher doses and that the placenta, a 2-pound temporary organ of pregnancy, is why.

"The idea that we are developing is that pregnant women are so different from non-pregnant women in terms of drug handling," said Dr. Vadivel Ganapathy, biochemist and interim chairman of the MCG Department of Biochemistry and Molecular Biology. "In non-pregnant women, only the intestine, liver and kidney are important to drug handling."



But the placenta – where mother and fetus connect and the fetus’ source of nutrients and oxygen – also can metabolize many drugs so they no longer function as drugs or it can transport drugs directly to the fetus.

"Normally the placenta is believed to be a barrier, a protective mechanism for the baby, so if the mother’s blood contains some drugs, the placenta is believed not to let it go the fetus. But that is not true for all drugs," said Dr. Ganapathy, who has studied the placenta’s interactions with everything from street drugs to folic acid.

He has cloned a transport system expressed in high levels in the placenta – called an organic cation transporter, or OCT3, because it can handle a broad spectrum of therapeutic drugs that contain a positive charge. "We are still trying to figure out the physiological role of this transporter, but we know it transports a lot of drugs," he said.

Now, as part of a National Institutes of Health Program Project grant at the University of Washington at Seattle, he is using the drug-handling capacity of this transporter to study the impact of pregnancy on drug efficacy. He’ll be looking at how the transporter impacts drugs levels in animal models as well as human placental cells in culture.

"We ought to know more about the placenta, what it does in terms of drugs, before we give the same dosage, the same regimen to pregnant women that we give to non-pregnant women," Dr. Ganapathy said.

As an example, the common anti-ulcer medication, cimetidine, known by the trade name Tagamet, readily interacts with the cation transporter. He’s using that drug to learn how much the drug level in the blood is affected by pregnancy. "A lower blood level may be innocuous with cimetidine, but what if you are treating a patient who has AIDS with anti-viral drugs?" Dr. Ganapathy said. "In a non-pregnant state, this particular anti-viral drug at a given dose is very good at keeping the level of HIV low in the blood. Now, if that HIV patient is pregnant and you give the same drug at the same dosage, that might not be enough to keep the viral load low. The viral load increases in the mother’s blood which also increases the chance of passing it through the placenta and on to the baby."

Animal studies examining a drug’s impact on a developing fetus are routinely done as part of drug development and Dr. Ganapathy will be doing that as part of his study, too. These fetal studies sometimes show that medications can’t be taken during pregnancy at any dose.

But studies on the impact on drug efficacy for the mothers-to-be have not been pursued, Dr. Ganapathy said, and dosages typically are not altered for those women.

This issue is central to the five-year study at MCG and the University of Washington, which was recently established as one of 11 new Specialized Centers of Research on Sex and Gender Factors by the NIH.

"We will look at the organic cation transporter, or OCT3, which is expressed primarily in the placenta and handles a lot of drugs, as a way to characterize the drugs normally used in pregnant women which can be handled by this transporter," Dr. Ganapathy said of his $1.5 million grant. "These drugs should be flagged saying the efficacy of the drug may be altered during pregnancy because you have this transporter sitting there during pregnancy which can transport these drugs, take it away from the mother and put it into the baby." Dr. Puttur D. Prasad, researcher in the MCG Department of Obstetrics and Gynecology, is a co-investigator on Dr. Ganapathy’s study.

Related studies at the University of Washington will use non-therapeutic doses of common, non-toxic drugs to see if blood levels vary in pregnant versus non-pregnant women and primates.

Toni Baker | EurekAlert!
Further information:
http://www.mcg.edu/

More articles from Health and Medicine:

nachricht Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>